DoxyPEP: Opportunities for Expansion.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40913480.
- Also identified by DOI 10.1177/21501319251370497 and PMC identifier 12414116.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trials show that doxycycline post-exposure prophylaxis (DoxyPEP) significantly reduces the risk of bacterial sexually transmitted infections (STIs), especially syphilis and chlamydia, in cisgender men who have sex with men and transgender women. Real-world data suggest DoxyPEP may be beneficial for other populations disproportionately affected by STIs. Given the ongoing STI epidemic we recommend discussing DoxyPEP with all eligible patients. We review clinical guidelines and practical considerations surrounding DoxyPEP, highlight areas for future research, and propose strategies for implementation.
Medical subject headings
- Anti-Bacterial Agents
- Doxycycline
- Post-Exposure Prophylaxis
- Sexually Transmitted Diseases